Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection.

Standard

Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. / Burkhardt, O; Ewig, S; Haagen, U; Giersdorf, S; Hartmann, O; Wegscheider, Karl; Hummers-Pradier, E; Welte, T.

In: EUR RESPIR J, Vol. 36, No. 3, 3, 2010, p. 601-607.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Burkhardt, O, Ewig, S, Haagen, U, Giersdorf, S, Hartmann, O, Wegscheider, K, Hummers-Pradier, E & Welte, T 2010, 'Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection.', EUR RESPIR J, vol. 36, no. 3, 3, pp. 601-607. <http://www.ncbi.nlm.nih.gov/pubmed/20185423?dopt=Citation>

APA

Burkhardt, O., Ewig, S., Haagen, U., Giersdorf, S., Hartmann, O., Wegscheider, K., Hummers-Pradier, E., & Welte, T. (2010). Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. EUR RESPIR J, 36(3), 601-607. [3]. http://www.ncbi.nlm.nih.gov/pubmed/20185423?dopt=Citation

Vancouver

Burkhardt O, Ewig S, Haagen U, Giersdorf S, Hartmann O, Wegscheider K et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. EUR RESPIR J. 2010;36(3):601-607. 3.

Bibtex

@article{ec80e9d1ec624cb8a4a790b85decab94,
title = "Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection.",
abstract = "Increasing worldwide development of antimicrobial resistance and the association of resistance development and antibiotic overuse make it necessary to seek strategies for safely reducing antibiotic use and selection pressure. In a first step, in a non-interventional study, the antibiotic prescription rates, initial procalcitonin (PCT) levels and outcome of 702 patients presenting with acute respiratory infection at 45 primary care physicians were observed. The second part was a randomised controlled non-inferiority trial comparing standard care with PCT-guided antimicrobial treatment in 550 patients in the same setting. Antibiotics were recommended at a PCT threshold of 0.25 ng·mL(-1). Clinical overruling was permitted. The primary end-point for non-inferiority was number of days with significant health impairment after 14 days. Antibiotics were prescribed in 30.3% of enrolled patients in the non-interventional study. In the interventional study, 36.7% of patients in the control group received antibiotics as compared to 21.5% in the PCT-guided group (41.6% reduction). In the modified intention-to-treat analysis, the numbers of days with significant health impairment were similar (mean 9.04 versus 9.00 for PCT-guided and control group, respectively; difference 0.04; 95% confidence interval -0.73-0.81). This was also true after adjusting for the most important confounders. In the PCT group, advice was overruled in 36 cases. There was no significant difference in primary end-point when comparing the PCT group treated as advised, the overruled PCT group and the control group (9.008 versus 9.250 versus 9.000 days; p = 0.9605). A simple one-point PCT measurement for guiding decisions on antibiotic treatment is non-inferior to standard treatment in terms of safety, and effectively reduced the antibiotic treatment rate by 41.6%.",
keywords = "Adult, Humans, Aged, Middle Aged, Aged, 80 and over, Adolescent, Treatment Outcome, Sensitivity and Specificity, Follow-Up Studies, administration, Anti-Bacterial Agents pharmacology, Calcitonin chemistry, Primary Health Care organization, Protein Precursors chemistry, Pulmonary Medicine methods, Respiratory Tract Infections drug therapy, Adult, Humans, Aged, Middle Aged, Aged, 80 and over, Adolescent, Treatment Outcome, Sensitivity and Specificity, Follow-Up Studies, administration, Anti-Bacterial Agents pharmacology, Calcitonin chemistry, Primary Health Care organization, Protein Precursors chemistry, Pulmonary Medicine methods, Respiratory Tract Infections drug therapy",
author = "O Burkhardt and S Ewig and U Haagen and S Giersdorf and O Hartmann and Karl Wegscheider and E Hummers-Pradier and T Welte",
year = "2010",
language = "Deutsch",
volume = "36",
pages = "601--607",
journal = "EUR RESPIR J",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

RIS

TY - JOUR

T1 - Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection.

AU - Burkhardt, O

AU - Ewig, S

AU - Haagen, U

AU - Giersdorf, S

AU - Hartmann, O

AU - Wegscheider, Karl

AU - Hummers-Pradier, E

AU - Welte, T

PY - 2010

Y1 - 2010

N2 - Increasing worldwide development of antimicrobial resistance and the association of resistance development and antibiotic overuse make it necessary to seek strategies for safely reducing antibiotic use and selection pressure. In a first step, in a non-interventional study, the antibiotic prescription rates, initial procalcitonin (PCT) levels and outcome of 702 patients presenting with acute respiratory infection at 45 primary care physicians were observed. The second part was a randomised controlled non-inferiority trial comparing standard care with PCT-guided antimicrobial treatment in 550 patients in the same setting. Antibiotics were recommended at a PCT threshold of 0.25 ng·mL(-1). Clinical overruling was permitted. The primary end-point for non-inferiority was number of days with significant health impairment after 14 days. Antibiotics were prescribed in 30.3% of enrolled patients in the non-interventional study. In the interventional study, 36.7% of patients in the control group received antibiotics as compared to 21.5% in the PCT-guided group (41.6% reduction). In the modified intention-to-treat analysis, the numbers of days with significant health impairment were similar (mean 9.04 versus 9.00 for PCT-guided and control group, respectively; difference 0.04; 95% confidence interval -0.73-0.81). This was also true after adjusting for the most important confounders. In the PCT group, advice was overruled in 36 cases. There was no significant difference in primary end-point when comparing the PCT group treated as advised, the overruled PCT group and the control group (9.008 versus 9.250 versus 9.000 days; p = 0.9605). A simple one-point PCT measurement for guiding decisions on antibiotic treatment is non-inferior to standard treatment in terms of safety, and effectively reduced the antibiotic treatment rate by 41.6%.

AB - Increasing worldwide development of antimicrobial resistance and the association of resistance development and antibiotic overuse make it necessary to seek strategies for safely reducing antibiotic use and selection pressure. In a first step, in a non-interventional study, the antibiotic prescription rates, initial procalcitonin (PCT) levels and outcome of 702 patients presenting with acute respiratory infection at 45 primary care physicians were observed. The second part was a randomised controlled non-inferiority trial comparing standard care with PCT-guided antimicrobial treatment in 550 patients in the same setting. Antibiotics were recommended at a PCT threshold of 0.25 ng·mL(-1). Clinical overruling was permitted. The primary end-point for non-inferiority was number of days with significant health impairment after 14 days. Antibiotics were prescribed in 30.3% of enrolled patients in the non-interventional study. In the interventional study, 36.7% of patients in the control group received antibiotics as compared to 21.5% in the PCT-guided group (41.6% reduction). In the modified intention-to-treat analysis, the numbers of days with significant health impairment were similar (mean 9.04 versus 9.00 for PCT-guided and control group, respectively; difference 0.04; 95% confidence interval -0.73-0.81). This was also true after adjusting for the most important confounders. In the PCT group, advice was overruled in 36 cases. There was no significant difference in primary end-point when comparing the PCT group treated as advised, the overruled PCT group and the control group (9.008 versus 9.250 versus 9.000 days; p = 0.9605). A simple one-point PCT measurement for guiding decisions on antibiotic treatment is non-inferior to standard treatment in terms of safety, and effectively reduced the antibiotic treatment rate by 41.6%.

KW - Adult

KW - Humans

KW - Aged

KW - Middle Aged

KW - Aged, 80 and over

KW - Adolescent

KW - Treatment Outcome

KW - Sensitivity and Specificity

KW - Follow-Up Studies

KW - administration

KW - Anti-Bacterial Agents pharmacology

KW - Calcitonin chemistry

KW - Primary Health Care organization

KW - Protein Precursors chemistry

KW - Pulmonary Medicine methods

KW - Respiratory Tract Infections drug therapy

KW - Adult

KW - Humans

KW - Aged

KW - Middle Aged

KW - Aged, 80 and over

KW - Adolescent

KW - Treatment Outcome

KW - Sensitivity and Specificity

KW - Follow-Up Studies

KW - administration

KW - Anti-Bacterial Agents pharmacology

KW - Calcitonin chemistry

KW - Primary Health Care organization

KW - Protein Precursors chemistry

KW - Pulmonary Medicine methods

KW - Respiratory Tract Infections drug therapy

M3 - SCORING: Zeitschriftenaufsatz

VL - 36

SP - 601

EP - 607

JO - EUR RESPIR J

JF - EUR RESPIR J

SN - 0903-1936

IS - 3

M1 - 3

ER -